Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

675.79 -18.85 (-2.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
43 44 Next >
If You Invested $100 In This Stock 20 Years Ago, You Would Have $5,000 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.25% on an annualized basis producing an average annual return of 21.62%. Currently, Regeneron... 
Via Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022
Upgrades 
Via Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings: 
Via Benzinga
13 Analysts Have This to Say About Regeneron Pharmaceuticals
Over the past 3 months, 13 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Why Cash-Rich Companies And #ETFs Are Beating The Market?
Investors believe that “cash is king” in the current environment of surging inflation, rising rates, and a potential economic downturn. ETFs that hold cash-rich companies have seen a lot of interest... 
Via Talk Markets
3 Red-Hot Stocks That Could Continue to Beat the Market
Investors are betting on these companies' revenue growth prospects. 
Via The Motley Fool
Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product
Via Benzinga
Moderna, Eli Lilly And This Biotechnology Stock Insiders Are Selling
The Nasdaq Composite tumbled by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
These 7 Biotech Stocks Are Set to Boom in 2023
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023 
Via InvestorPlace
2 Top Healthcare Stocks to Buy Right Now
Healthcare is about as sticky of a business model as you'll find. 
Via The Motley Fool
Eaton, Wynn Resorts, Lamar Advertising And This Pharma Company Are CNBC's Final Trades
On CNBC’s “Halftime Report Final Trades,” Kevin O'Leary, known as "Mr. Wonderful," chose Lamar Advertising Co. (NASDAQ: LAMR). 
Via Benzinga
Apple Short Sellers Made $2B In Profits In September, And Shorts In This Biotech Stock Lost $307M
The SPDR S&P 500 ETF Trust (NYSE: SPY) struggled in September, historically its worst month of the year. 
Via Benzinga
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio. 
Via Talk Markets
13 Analysts Have This to Say About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Regeneron Pharmaceuticals Whale Trades For October 03
Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on... 
Via Benzinga
What 13 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings: 
Via Benzinga
Hopeful Golden Cross Forms On Regeneron Pharmaceuticals's Chart
If history is any guide, there may be good fortune ahead for shares of Regeneron Pharmaceuticals (NASDAQ:REGN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
The One-Minute Market Report - Sunday, Oct. 2
In today's issue of the One-Minute Market Report, I examine the damage done in September and highlight the parts of the market that were hit the hardest. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
Via Benzinga
Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea
Via Benzinga
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market. 
Via InvestorPlace
Can Healthcare Stocks Continue To Outperform?
Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis. 
Via Talk Markets
The Top 5 Stocks Cathie Wood Is Buying This Week
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys. 
Via InvestorPlace
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.71% on an annualized basis producing an average annual return of 16.96%. Currently, Regeneron... 
Via Benzinga
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
Via Benzinga
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.